Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial - Wikidata - wikimedia - TriplyDB

Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial

Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial

http://www.wikidata.org/entity/Q28294892

about

Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents Epigenetic deregulation of microRNAs in rhabdomyosarcoma and neuroblastoma and translational perspectives Trials with 'epigenetic' drugs: an update Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications.New perspectives of valproic acid in clinical practice.Epigenetics of discordant monozygotic twins: implications for disease Small-molecular modulators of cancer-associated epigenetic mechanisms.Acute myeloid leukaemia: optimal management and recent developments.Repurposing FDA-approved drugs for anti-aging therapies.Selective non-nucleoside inhibitors of human DNA methyltransferases active in cancer including in cancer stem cells.DNA Methylation Targeting: The DNMT/HMT Crosstalk Challenge.MicroRNAs in rhabdomyosarcoma: pathogenetic implications and translational potentiality.Epigenetic drug discovery: targeting DNA methyltransferases.Epigenetic changes in patients with multiple sclerosis.Role of epigenetics in chronic myeloid leukemia Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer.DNA methyltransferase inhibitors: an updated patent review (2012-2015).DNA Methyltransferase Inhibitors: Development and Applications.A chemical probe toolbox for dissecting the cancer epigenome.The antihypertensive drug hydralazine activates the intrinsic pathway of apoptosis and causes DNA damage in leukemic T cells.Docking of a novel DNA methyltransferase inhibitor identified from high-throughput screening: insights to unveil inhibitors in chemical databases.Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS).Efficacy of hydralazine and valproate in cutaneous T-cell lymphoma, a phase II study.

P2860

Q24633763-AB479CEF-E9D7-47B7-9E99-4321A31843CB Q26999187-4AD9AC9B-1803-4B3C-8A8D-D0D22AFFCA9D Q27000542-148C2A9A-013C-4FD3-BE37-21AE8BF74818 Q28236628-A2E84A07-DDBC-47E6-86CD-29EDB6F07C14 Q33910609-49C8F6A2-F5F8-4A90-934D-2C02291E417A Q34380256-9BE25082-D82F-4A3E-9D7C-4983464A939C Q34624829-9EC34890-B5B3-487A-B592-CB3763613CEE Q34628002-7D80ADF1-DA26-4495-82BA-E49EE8F43317 Q36914091-254FE32C-C936-4894-9712-374E171470AC Q37341939-E9BF4D08-9BBF-45BB-AE22-E9E86066C642 Q37697396-88DA56A9-8A12-4D82-B765-0B18DA94FCFB Q37729405-6B3C7FE8-C786-4C20-A64A-B2E5AB337D80 Q37937737-0B1BFCB9-209F-40E6-8698-CB136A5EA38A Q37941536-5B37501E-2AFF-4D0C-8FC7-1C9F162AA6D2 Q38061010-79745478-1720-4BD3-A771-2E5BAEF7A9F6 Q38072315-938B7F0A-97E8-426E-8380-9F47CC32F39A Q38242979-36E4C643-D031-4D5E-828B-B24F239BEBA1 Q38885370-92AE369E-72CA-4EE6-8DE1-60301EE23F76 Q39003558-D3DF60F2-6F1D-4154-88E5-ACDF4761FB47 Q39147132-1D5DC69A-1D01-450E-AA68-A1BC93CCBFEA Q40996500-567E09BD-D0FA-4C13-A862-91CB303FC9F5 Q45191168-DD981176-0DD2-47A0-AFF3-C579F0106CE8 Q48198254-84727EFB-2EAB-4355-9552-8A92F9EEA6EC Q50853522-BBFCFC86-B739-4530-8E3D-55192A547691

P2860

Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial

http://www.wikidata.org/entity/Q28294892

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Hydralazine and magnesium valp ...... ry results of a phase-II trial

@ast

Hydralazine and magnesium valp ...... ry results of a phase-II trial

@en

Hydralazine and magnesium valp ...... ry results of a phase-II trial

@nl

type

label

Hydralazine and magnesium valp ...... ry results of a phase-II trial

@ast

Hydralazine and magnesium valp ...... ry results of a phase-II trial

@en

Hydralazine and magnesium valp ...... ry results of a phase-II trial

@nl

prefLabel

Hydralazine and magnesium valp ...... ry results of a phase-II trial

@ast

Hydralazine and magnesium valp ...... ry results of a phase-II trial

@en

Hydralazine and magnesium valp ...... ry results of a phase-II trial

@nl

P1433

Q28294892-DE0DB5BA-2721-4ECE-AD0D-D98372D3B90A

P1476

Q28294892-37057CCA-2BFB-4F6B-82DA-8928996BEDC8

P2093

Q28294892-19A18B4E-84D1-489F-BC8E-1E6ED74B8D9E

Q28294892-51B5315D-1775-40A4-BA49-26207DADBAB1

Q28294892-53854E6D-7B21-451D-89BC-E2BD6A770D6E

Q28294892-54BD20C8-4A4C-4610-BABC-EE39D9FF076F

Q28294892-55D004BA-1338-4D3D-9FF3-CBA20F684F98

Q28294892-7DA207FD-92BF-4131-85E6-FDDAAA5E2DCA

Q28294892-88555028-EBB0-48D0-B141-3EB2E5C1BA72

Q28294892-8A3303F2-9E9C-4A9E-BE70-9E1DF552E9E3

Q28294892-ADCD25DB-4117-4219-816D-70FD15D8E271

Q28294892-B0F18E1D-6097-4A1D-8564-B76B916660E0

P2860

Q28294892-017187C0-B2F0-4385-8FD3-95BD05DB25E3

Q28294892-06E21DA3-00F3-4DD1-B831-86DE8429FE21

Q28294892-1DA787D4-21B4-4CF9-A468-B42BACE9588C

Q28294892-1F2C6159-0B43-4E3B-B534-22BE8C98445E

Q28294892-2B4BC417-647C-4B16-A536-75BE6DE66A1D

Q28294892-37D19732-C180-40BB-85E5-A19CB45FEECA

Q28294892-3844D732-9345-4C3B-8FD0-EC2FE14FF0F0

Q28294892-3C16EE8D-0891-4568-B438-86FC88AFF8E2

Q28294892-4B94D619-69AE-480F-8989-B0CDD3376DCA

Q28294892-4F500DFD-F096-4E88-A7E7-C10E08F872BD

P304

Q28294892-0A33D640-C433-432C-BF86-EC9E8970181C

P31

Q28294892-B7A055C5-AEDE-4950-9F82-26794CE6B238

P3181

Q28294892-697CE27A-9775-43BF-BCF5-BC75DFA8A7D4

P356

Q28294892-9030B0AF-4803-400A-9664-A8EAA924E244

P407

Q28294892-281F2C15-29AD-4F62-9150-69D43F0CF951

P433

Q28294892-DD4D7F08-C7A0-467D-8C58-19AC3E7347F1

P478

Q28294892-543A5316-1909-4446-A2DC-71CDF6337CA8

P577

Q28294892-E8067A13-F06F-4FC8-82F1-2B839F5B23E8

P5875

Q28294892-28459AF6-3A04-4CC7-86A8-7FA946830236

P698

Q28294892-F98F02A8-E441-4A36-AF91-E8CB67818D4C

P921

Q28294892-34453587-b12d-4a55-b8e1-29f8aff173a7

Q28294892-8F035C45-008F-45A1-A413-15E295DCB034

P3181

P356

S00277-010-1090-2

P1433

Annals of Hematology

P1476

Hydralazine and magnesium valp ...... ry results of a phase-II trial

@en

P2093

Alfonso Dueñas-Gonzalez

http://www.w3.org/2001/XMLSchema#string

Aquileo Herrera

http://www.w3.org/2001/XMLSchema#string

Aurora González-Fierro

http://www.w3.org/2001/XMLSchema#string

Catalina Trejo-Becerril

http://www.w3.org/2001/XMLSchema#string

Daymi Arias-Bofill

http://www.w3.org/2001/XMLSchema#string

Eduardo Cervera

http://www.w3.org/2001/XMLSchema#string

Enrique Pérez-Cárdenas

http://www.w3.org/2001/XMLSchema#string

Erick de la Cruz-Hernández

http://www.w3.org/2001/XMLSchema#string

Juan Labardini

http://www.w3.org/2001/XMLSchema#string

Lucía Taja-Chayeb

http://www.w3.org/2001/XMLSchema#string

P2860

A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes

Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines.

Epigenetics in human disease and prospects for epigenetic therapy

A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.

DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes

Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.

Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors.

Demethylating agents in myeloid malignancies.

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.

Recent advances in myelodysplastic syndromes.

P304

379-87

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4348476

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S00277-010-1090-2

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

90

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47337701

http://www.w3.org/2001/XMLSchema#string

P698

20922525

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

Béésh Łikoní